Developer docs
API playgroundTry for free, no card

Search company profiles

Intract Pharma

Full company profile

uuid00091mk

Namestring
Intract Pharma
Legal namestring
Intract Pharma Ltd
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Intract Pharma Ltd is a UK-based oral drug delivery licensing and product development company founded in 2015 as a spin-out from University College London's School of Pharmacy, where founder Prof. Abdul Basit led more than 20 years of research in gastrointestinal drug delivery. The company's core offerings are two proprietary platform technologies: Phloral®, a dual-trigger enteric coating that combines pH-sensitive and bacterially (enzyme) triggered release mechanisms to deliver drugs to the colon; and Soteria®, which enables monoclonal antibodies, peptides and proteins to be administered orally as tablets or capsules by protecting them from enzymatic degradation and enhancing uptake into colonic tissue. Supporting scientific services include the patented Auto pH System™-driven Dynamic Dissolution Model and a suite of GI Stability and Permeability Models using human and animal biological fluids, plus complementary release technologies (Duocoat®, ProRelease®).

The commercial model is B2B technology licensing and collaborative preclinical R&D. Intract licenses Phloral® and Soteria® to pharmaceutical and biotechnology companies, retaining upfront fees, development and regulatory milestone payments, and mid-single-digit royalties on net sales; the firm also leads preclinical formulation work for partners under fee-for-service research agreements. Customers include Tillotts Pharma AG (commercialised Yaldigo/Asacol 1600 with Phloral® in 2019), Tharimmune (global exclusive license for oral infliximab INT-023/TH023, $200M+ in potential milestones), Celltrion (oral infliximab, MHRA Phase 1b/2a cleared), Bio-Thera Solutions, Elasmogen, Ferring Pharmaceuticals, Merck & Co., Bio-Sourcing, Neopharma Japan, NIBEC, and N&S Pharmacy Investment, with grant funding from Innovate UK, the EPSRC and the Bill & Melinda Gates Foundation.

Geographically the firm serves partners across Europe (UK, Switzerland, Germany), North America and the Asia-Pacific region (South Korea, China, Japan, MENA). In September 2024 Intract signed a nonbinding letter of intent to merge with Tharimmune, under which Intract shareholders would hold 49% of the combined entity; closing was anticipated in the first quarter of 2025. The firm is privately held, employs 1–10 staff and is operated from a 1,500 sq ft combined lab/office suite at the London Bioscience Innovation Centre.

Short descriptiontext

Intract Pharma is a London-based oral drug delivery licensing company that develops proprietary colon-targeting (Phloral®) and oral biologics-delivery (Soteria®) platforms for pharmaceutical and biotechnology partners, monetising through upfronts, milestones and royalties.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oral drug delivery, biologics delivery platform, colon-targeted formulations, enteric coating technology, biopharmaceutical licensing
Industry3 codes
PRIMARYHLAGAHAI
Solid-State Chemistry & Preformulation (Polymorph/Crystallization)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAIACAE
Gastroenterology Specialty Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Medical Laboratories8071
Product category
Oral Drug Delivery Technologies
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Technology Licensing
TypeLicensing Royalties
Description

Licensing of proprietary technologies (Phloral®, Soteria®) to pharmaceutical partners for development and commercialization of oral biologic products. Receives upfront payments, development milestones, regulatory milestones, and commercial royalties (mid-single digit royalties on net product sales).

intractpharma.com
2Collaborative Research & Development
TypeProfessional Services
Description

Research collaboration agreements where Intract leads preclinical research while partners provide funding, drug materials, and later handle manufacturing and commercialization. Receives technology access fees, milestone payments, and tiered royalties.

intractpharma.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Intract Pharma develops and licenses proprietary oral drug delivery technology platforms that allow biopharmaceutical drugs — including monoclonal antibodies, peptides and proteins — to be administered as tablets or capsules and released at targeted gastrointestinal sites (notably the colon). Its commercial core offerings are the Phloral® dual-trigger enteric coating and the Soteria® oral biologics platform, supported by proprietary GI testing services (Dynamic Dissolution Model and Gastrointestinal Stability/Permeability Models) and enabling release technologies (Duocoat®, ProRelease®, Auto pH System™). Revenue is generated by licensing these technologies to pharma/biotech partners and through collaborative R&D agreements, earning upfront payments, development and regulatory milestones, and royalties.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 88% per-protocol efficacy demonstrated with Phloral®-coated microbial therapeutic (FIN-403) in dose-finding study with 26 patients
+3 more records
Product overview1 text field

Intract Pharma is a biopharmaceutical company offering a platform of oral drug delivery technologies centered around two core proprietary technologies: Phloral® (the world's only dual-trigger enteric coating technology combining pH and bacterial enzyme triggers for guaranteed colon delivery) and Soteria® (a revolutionary technology enabling oral delivery of biopharmaceuticals including monoclonal antibodies as tablets/capsules). These core technologies are supported by proprietary GI testing services including the Dynamic Dissolution Model and GI Stability/Permeability Models, plus additional release technologies (Duocoat®, ProRelease®) and the patented Auto pH System™. The platform enables precise targeting of drugs to the colon while protecting biologics from enzymatic breakdown, allowing tissue or systemic uptake.

Product and service4 records
1Phloral®
CategoryOral drug delivery technology platform — colon-targeted enteric coating
Description

Dual-trigger enteric coating technology that combines gastrointestinal pH changes with the enzymatic activity of colonic microbiota as independent but complementary release mechanisms to guarantee site-specific release of drugs in the colon. Licensed to pharmaceutical and biotechnology companies for formulation of colon-targeted therapeutics, including the commercialized Yaldigo®/Asacol 1600 (mesalazine) for ulcerative colitis.

2Soteria®
CategoryOral drug delivery technology platform — biologics delivery
Description

Technology enabling oral delivery of biopharmaceutical drugs including monoclonal antibodies, peptides and proteins as tablets or capsules. Protects the biologic from enzymatic degradation in the GI tract while enhancing uptake into colon tissue, then uses Phloral® coating for colon targeting. Licensed to pharma/biotech partners (Bio-Thera Solutions, Celltrion, Tharimmune, Elasmogen, Ferring) for development of oral antibody and peptide therapeutics, particularly in inflammatory bowel disease and autoimmune indications.

3Dynamic Dissolution Model
CategoryGI modeling and drug development service
Description

Advanced bio-relevant in vitro dissolution testing service incorporating bicarbonate-based media controlled by a patented Auto pH System™ to simulate the dynamic pH and transit environment of the GI tract. Provided to pharmaceutical and biotech partners for formulation development and IVIVIC analysis.

4Gastrointestinal Stability and Permeability Models
CategoryGI modeling and drug development service
Description

In vitro and ex vivo gastrointestinal modeling services using human and animal GI fluids and tissues to evaluate drug solubility, stability, localization and permeation throughout gastric, small intestinal and colon compartments. Used to support formulation development under Phloral® and Soteria® programs.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership17 partners
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-09-16
Description

Tharimmune acquired global exclusive license (outside South Korea) to Intract's Soteria® and Phloral® delivery platform for INT-023/TH023, an oral anti-TNFα mAb (infliximab) for autoimmune diseases. Intract received single-digit million upfront payment and is eligible for $200M+ in milestones plus mid-single digit royalties. Tharimmune also has option for up to four additional targets. September 2024 LOI announced for merger with Tharimmune.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-05-28
Description

AB-BIOBETTER project - €3.4M EU-funded program (€1.9M from EUREKA Eurostars) to develop oral formulation of adalimumab for IBD. Bio-Sourcing leads with BioMilk platform for antibody production; Intract provides delivery and stabilization technologies. Three-year project aims for IND-enabling studies.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-05-28
Description

French preclinical biotech contributing extracellular vesicle bioengineering expertise for oral administration of antibody therapeutics in AB-BIOBETTER project.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-11-08
Description

Publication of pre-clinical proof-of-concept study on colon targeted delivery of JAK inhibitor tofacitinib using Phloral® technology. 3-year collaboration demonstrated enhanced tissue PK and reduced systemic PK leading to superior IL6 downregulation in rat colitis model.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2022-09-16
Description

Global license agreement giving Elasmogen exclusive access to Soteria® and Phloral® for oral colonic delivery of soloMER™ protein therapeutics for Crohn's disease and ulcerative colitis. Builds on 2020 research collaboration. Intract receives undisclosed upfront, milestones, and royalties. Elasmogen can expand for four additional targets.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2021-09-27
Description

Global collaboration and license agreement granting Bio-Thera worldwide license to Intract's oral biologics delivery platform for single undisclosed mAb product for chronic GI inflammatory diseases. Intract leads preclinical research; Bio-Thera handles manufacturing and commercialization. Intract receives undisclosed upfront, milestones, and royalties.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-04-22
Description

Research collaboration to evaluate Intract's oral biologics delivery platform for developing oral dual-targeting peptide therapeutic (NIPEP-IBD) for ulcerative colitis. Intract optimizes intestinal stability and tissue uptake.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-04-01
Description

Research collaboration to investigate oral delivery of undisclosed interleukin-targeting mAb for IBD using Phloral® and Soteria® technologies for precision oral delivery directly to GI tissue.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-08-20
Description

Joint development agreement for world's first oral antibody therapeutic for IBD (oral infliximab). Intract leads development; Celltrion supplies drug material and retains right to complete clinical development after Phase 2. Product cleared for Phase 1b/2a trials in IBD patients by UK MHRA.

10N&S Pharmacy Investment
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-05-26
Description

Partnership to develop orally-delivered GLP-1R agonist peptide for metabolic diseases. N&S Pharmacy funds feasibility studies with exclusive option to global royalty-based license. HEC Group involved in later pre-clinical/clinical development in China.

intractpharma.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-05-05
Description

Initial research collaboration to discover and develop novel orally-delivered protein therapeutics combining Elasmogen's soloMER™ technology with Intract's Soteria® and Phloral® for GI indications.

12Carus Animal Health
Strategic tierMinorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2019-05-07
Description

Agreement to develop Intract's drug delivery technologies for veterinary market for treatment of companion animals. Carus is UK company with parent Kyoritsu Seiyaku (Japan, #11 global animal health).

intractpharma.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2019-04-05
Description

Collaboration to develop novel therapeutic product for GI diseases using Intract's proprietary drug delivery technologies. Neopharma is subsidiary of Neopharma UAE (largest pharma in MENA region, 50+ countries).

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2019-03-27
Description

Phloral® technology licensed to Tillotts for use with mesalazine. First Phloral® colon-targeting product Yaldigo®/Asacol 1600 launched for ulcerative colitis treatment - landmark validation of technology.

Strategic tierMinorTypeImplementation/ SI/ Consulting PartnerAnnounced on2018-11-09
Description

Part of Innovate UK consortium for developing scalable manufacturing process for oral antibody products using Soteria® technology.

Strategic tierMinorTypeImplementation/ SI/ Consulting PartnerAnnounced on2018-11-09
Description

Part of Innovate UK consortium providing drug development and manufacture expertise.

Strategic tierMinorTypeImplementation/ SI/ Consulting PartnerAnnounced on2018-11-09
Description

Part of Innovate UK consortium providing formulation and analytical development expertise for scalable manufacturing.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

Clinical-stage company developing oral formulations of peptides and large molecules (e.g., oral PTH, GLP-1) — a directly comparable oral-biologics delivery business pursuing the same licensing/partnering playbook as Intract.

TypeDirect peer
Description

Developer of an oral 'robotic pill' (RaniPill) for systemic delivery of biologics including peptides, proteins and antibodies — a head-to-head technical alternative to Intract's Soteria® approach aimed at the same pharmaceutical partners.

3Applied Molecular Transport
TypeDirect peer
Description

Biotech developing oral biologics using a proprietary technology platform, with lead programs in IBD and other GI indications — same therapeutic focus (GI) and same oral-biologics platform-licensing model as Intract.

TypeBroad incumbent
Description

Global CDMO with deep oral drug delivery and softgel/Zydis formulation capabilities frequently used by pharma for colon-targeted and modified-release products — competes for the same partner-funded formulation development work Intract services.

TypeBroad incumbent
Description

Large-scale CDMO offering oral drug delivery technologies, encapsulation and bioavailability enhancement; the broader incumbent that sponsors evaluate when scouting oral-formulation partners alongside Intract.

6Evonik (Health Care)
TypeBroad incumbent
Description

CDMO with EUDRACAP®, EUDRAGIT® and other oral-functional excipient/platform technologies used by pharma for enteric and colonic delivery — overlaps with Intract's Phloral® dual-trigger coating positioning.

TypeEmerging player
Description

Developer of oral once-weekly sustained-release dosage forms for oral peptides and small molecules — adjacent oral-drug-delivery platform addressing the same patient-compliance thesis (replace frequent dosing/injections with oral formulations).

TypeOthers
Description

Merck's biopharmaceutical testing/services arm — relevant context because Intract has published pre-clinical work with Merck on colon-targeted tofacitinib; Intract sits as a niche complement/competitor rather than a substitute for Merck's broader services.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Intract Pharma

Oral Drug Delivery Technologiesintractpharma.com

Intract Pharma is a London-based oral drug delivery licensing company that develops proprietary colon-targeting (Phloral®) and oral biologics-delivery (Soteria®) platforms for pharmaceutical and biotechnology partners, monetising through upfronts, milestones and royalties.

What Intract Pharma does

Intract Pharma Ltd is a UK-based oral drug delivery licensing and product development company founded in 2015 as a spin-out from University College London's School of Pharmacy, where founder Prof. Abdul Basit led more than 20 years of research in gastrointestinal drug delivery. The company's core offerings are two proprietary platform technologies: Phloral®, a dual-trigger enteric coating that combines pH-sensitive and bacterially (enzyme) triggered release mechanisms to deliver drugs to the colon; and Soteria®, which enables monoclonal antibodies, peptides and proteins to be administered orally as tablets or capsules by protecting them from enzymatic degradation and enhancing uptake into colonic tissue. Supporting scientific services include the patented Auto pH System™-driven Dynamic Dissolution Model and a suite of GI Stability and Permeability Models using human and animal biological fluids, plus complementary release technologies (Duocoat®, ProRelease®).

The commercial model is B2B technology licensing and collaborative preclinical R&D. Intract licenses Phloral® and Soteria® to pharmaceutical and biotechnology companies, retaining upfront fees, development and regulatory milestone payments, and mid-single-digit royalties on net sales; the firm also leads preclinical formulation work for partners under fee-for-service research agreements. Customers include Tillotts Pharma AG (commercialised Yaldigo/Asacol 1600 with Phloral® in 2019), Tharimmune (global exclusive license for oral infliximab INT-023/TH023, $200M+ in potential milestones), Celltrion (oral infliximab, MHRA Phase 1b/2a cleared), Bio-Thera Solutions, Elasmogen, Ferring Pharmaceuticals, Merck & Co., Bio-Sourcing, Neopharma Japan, NIBEC, and N&S Pharmacy Investment, with grant funding from Innovate UK, the EPSRC and the Bill & Melinda Gates Foundation.

Geographically the firm serves partners across Europe (UK, Switzerland, Germany), North America and the Asia-Pacific region (South Korea, China, Japan, MENA). In September 2024 Intract signed a nonbinding letter of intent to merge with Tharimmune, under which Intract shareholders would hold 49% of the combined entity; closing was anticipated in the first quarter of 2025. The firm is privately held, employs 1–10 staff and is operated from a 1,500 sq ft combined lab/office suite at the London Bioscience Innovation Centre.

Intract Pharma firmographics

Firmographics
Name
Intract Pharma
Legal name
Intract Pharma Ltd
Website
https://intractpharma.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Intract Pharma is a London-based oral drug delivery licensing company that develops proprietary colon-targeting (Phloral®) and oral biologics-delivery (Soteria®) platforms for pharmaceutical and biotechnology partners, monetising through upfronts, milestones and royalties.
Ownership category
akta.pro rank

Intract Pharma industry classification

Industry
Product category
Oral Drug Delivery Technologies
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAGAHAI
Solid-State Chemistry & Preformulation (Polymorph/Crystallization)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAIACAE
Gastroenterology Specialty Pharmaceuticals

Keywords

  • Oral drug delivery
  • Biologics delivery platform
  • Colon-targeted formulations
  • Enteric coating technology
  • Biopharmaceutical licensing

Where Intract Pharma is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Intract Pharma business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Technology Licensing: Licensing of proprietary technologies (Phloral®, Soteria®) to pharmaceutical partners for development and commercialization of oral biologic products. Receives upfront payments, development milestones, regulatory milestones, and commercial royalties (mid-single digit royalties on net product sales).
  2. Collaborative Research & Development: Research collaboration agreements where Intract leads preclinical research while partners provide funding, drug materials, and later handle manufacturing and commercialization. Receives technology access fees, milestone payments, and tiered royalties.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Intract Pharma product offering

Product offering

Core offering

Intract Pharma develops and licenses proprietary oral drug delivery technology platforms that allow biopharmaceutical drugs — including monoclonal antibodies, peptides and proteins — to be administered as tablets or capsules and released at targeted gastrointestinal sites (notably the colon). Its commercial core offerings are the Phloral® dual-trigger enteric coating and the Soteria® oral biologics platform, supported by proprietary GI testing services (Dynamic Dissolution Model and Gastrointestinal Stability/Permeability Models) and enabling release technologies (Duocoat®, ProRelease®, Auto pH System™). Revenue is generated by licensing these technologies to pharma/biotech partners and through collaborative R&D agreements, earning upfront payments, development and regulatory milestones, and royalties.

Product overview

Intract Pharma is a biopharmaceutical company offering a platform of oral drug delivery technologies centered around two core proprietary technologies: Phloral® (the world's only dual-trigger enteric coating technology combining pH and bacterial enzyme triggers for guaranteed colon delivery) and Soteria® (a revolutionary technology enabling oral delivery of biopharmaceuticals including monoclonal antibodies as tablets/capsules). These core technologies are supported by proprietary GI testing services including the Dynamic Dissolution Model and GI Stability/Permeability Models, plus additional release technologies (Duocoat®, ProRelease®) and the patented Auto pH System™. The platform enables precise targeting of drugs to the colon while protecting biologics from enzymatic breakdown, allowing tissue or systemic uptake.

Differentiator

Problem solved

Functional benefit

Products and services

  • Phloral® Dual-trigger enteric coating technology that combines gastrointestinal pH changes with the enzymatic activity of colonic microbiota as independent but complementary release mechanisms to guarantee site-specific release of drugs in the colon. Licensed to pharmaceutical and biotechnology companies for formulation of colon-targeted therapeutics, including the commercialized Yaldigo®/Asacol 1600 (mesalazine) for ulcerative colitis.
  • Soteria® Technology enabling oral delivery of biopharmaceutical drugs including monoclonal antibodies, peptides and proteins as tablets or capsules. Protects the biologic from enzymatic degradation in the GI tract while enhancing uptake into colon tissue, then uses Phloral® coating for colon targeting. Licensed to pharma/biotech partners (Bio-Thera Solutions, Celltrion, Tharimmune, Elasmogen, Ferring) for development of oral antibody and peptide therapeutics, particularly in inflammatory bowel disease and autoimmune indications.
  • Dynamic Dissolution Model Advanced bio-relevant in vitro dissolution testing service incorporating bicarbonate-based media controlled by a patented Auto pH System™ to simulate the dynamic pH and transit environment of the GI tract. Provided to pharmaceutical and biotech partners for formulation development and IVIVIC analysis.
  • Gastrointestinal Stability and Permeability Models In vitro and ex vivo gastrointestinal modeling services using human and animal GI fluids and tissues to evaluate drug solubility, stability, localization and permeation throughout gastric, small intestinal and colon compartments. Used to support formulation development under Phloral® and Soteria® programs.

Quantifiable outcome

  • 88% per-protocol efficacy demonstrated with Phloral®-coated microbial therapeutic (FIN-403) in dose-finding study with 26 patients
  • +3 more outcomes

Companies that use Intract Pharma

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Intract Pharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Intract Pharma partnerships and signals

Strategic signal

Partnerships

17 partnerships are on record, tiered core and minor.

  • TharimmunecoreOEM/ Whitelabel/ Licensing Partner · 16 September 2024Tharimmune acquired global exclusive license (outside South Korea) to Intract's Soteria® and Phloral® delivery platform for INT-023/TH023, an oral anti-TNFα mAb (infliximab) for autoimmune diseases. Intract received single-digit million upfront payment and is eligible for $200M+ in milestones plus mid-single digit royalties. Tharimmune also has option for up to four additional targets. September 2024 LOI announced for merger with Tharimmune.
  • Bio-SourcingcoreStrategic or Co-development Partner · 28 May 2024AB-BIOBETTER project - €3.4M EU-funded program (€1.9M from EUREKA Eurostars) to develop oral formulation of adalimumab for IBD. Bio-Sourcing leads with BioMilk platform for antibody production; Intract provides delivery and stabilization technologies. Three-year project aims for IND-enabling studies.
  • CiloaminorStrategic or Co-development Partner · 28 May 2024French preclinical biotech contributing extracellular vesicle bioengineering expertise for oral administration of antibody therapeutics in AB-BIOBETTER project.
  • Merck & Co.coreStrategic or Co-development Partner · 8 November 2022Publication of pre-clinical proof-of-concept study on colon targeted delivery of JAK inhibitor tofacitinib using Phloral® technology. 3-year collaboration demonstrated enhanced tissue PK and reduced systemic PK leading to superior IL6 downregulation in rat colitis model.
  • ElasmogencoreOEM/ Whitelabel/ Licensing Partner · 16 September 2022Global license agreement giving Elasmogen exclusive access to Soteria® and Phloral® for oral colonic delivery of soloMER™ protein therapeutics for Crohn's disease and ulcerative colitis. Builds on 2020 research collaboration. Intract receives undisclosed upfront, milestones, and royalties. Elasmogen can expand for four additional targets.
  • Bio-Thera SolutionscoreOEM/ Whitelabel/ Licensing Partner · 27 September 2021Global collaboration and license agreement granting Bio-Thera worldwide license to Intract's oral biologics delivery platform for single undisclosed mAb product for chronic GI inflammatory diseases. Intract leads preclinical research; Bio-Thera handles manufacturing and commercialization. Intract receives undisclosed upfront, milestones, and royalties.
  • NIBECminorStrategic or Co-development Partner · 22 April 2021Research collaboration to evaluate Intract's oral biologics delivery platform for developing oral dual-targeting peptide therapeutic (NIPEP-IBD) for ulcerative colitis. Intract optimizes intestinal stability and tissue uptake.
  • Ferring PharmaceuticalscoreStrategic or Co-development Partner · 1 April 2021Research collaboration to investigate oral delivery of undisclosed interleukin-targeting mAb for IBD using Phloral® and Soteria® technologies for precision oral delivery directly to GI tissue.
  • Celltrion GroupcoreStrategic or Co-development Partner · 20 August 2020Joint development agreement for world's first oral antibody therapeutic for IBD (oral infliximab). Intract leads development; Celltrion supplies drug material and retains right to complete clinical development after Phase 2. Product cleared for Phase 1b/2a trials in IBD patients by UK MHRA.
  • N&S Pharmacy InvestmentminorStrategic or Co-development Partner · 26 May 2020Partnership to develop orally-delivered GLP-1R agonist peptide for metabolic diseases. N&S Pharmacy funds feasibility studies with exclusive option to global royalty-based license. HEC Group involved in later pre-clinical/clinical development in China.
  • ElasmogenminorStrategic or Co-development Partner · 5 May 2020Initial research collaboration to discover and develop novel orally-delivered protein therapeutics combining Elasmogen's soloMER™ technology with Intract's Soteria® and Phloral® for GI indications.
  • Carus Animal HealthminorOEM/ Whitelabel/ Licensing Partner · 7 May 2019Agreement to develop Intract's drug delivery technologies for veterinary market for treatment of companion animals. Carus is UK company with parent Kyoritsu Seiyaku (Japan, #11 global animal health).
  • Neopharma JapanminorStrategic or Co-development Partner · 5 April 2019Collaboration to develop novel therapeutic product for GI diseases using Intract's proprietary drug delivery technologies. Neopharma is subsidiary of Neopharma UAE (largest pharma in MENA region, 50+ countries).
  • Tillotts Pharma AGcoreOEM/ Whitelabel/ Licensing Partner · 27 March 2019Phloral® technology licensed to Tillotts for use with mesalazine. First Phloral® colon-targeting product Yaldigo®/Asacol 1600 launched for ulcerative colitis treatment - landmark validation of technology.
  • Centre for Process Innovation (CPI)minorImplementation/ SI/ Consulting Partner · 9 November 2018Part of Innovate UK consortium for developing scalable manufacturing process for oral antibody products using Soteria® technology.
  • PharmidexminorImplementation/ SI/ Consulting Partner · 9 November 2018Part of Innovate UK consortium providing drug development and manufacture expertise.
  • Quay PharmaceuticalsminorImplementation/ SI/ Consulting Partner · 9 November 2018Part of Innovate UK consortium providing formulation and analytical development expertise for scalable manufacturing.

Scale indicators7 records

Recent moves7 records

Expansion highlights7 records

Intract Pharma competitors and assessment

Company assessment

Direct peers

  • Entera Bio: Clinical-stage company developing oral formulations of peptides and large molecules (e.g., oral PTH, GLP-1) — a directly comparable oral-biologics delivery business pursuing the same licensing/partnering playbook as Intract.
  • Rani Therapeutics: Developer of an oral 'robotic pill' (RaniPill) for systemic delivery of biologics including peptides, proteins and antibodies — a head-to-head technical alternative to Intract's Soteria® approach aimed at the same pharmaceutical partners.
  • Applied Molecular Transport: Biotech developing oral biologics using a proprietary technology platform, with lead programs in IBD and other GI indications — same therapeutic focus (GI) and same oral-biologics platform-licensing model as Intract.

Broad incumbents

  • Catalent: Global CDMO with deep oral drug delivery and softgel/Zydis formulation capabilities frequently used by pharma for colon-targeted and modified-release products — competes for the same partner-funded formulation development work Intract services.
  • Lonza (Capsugel): Large-scale CDMO offering oral drug delivery technologies, encapsulation and bioavailability enhancement; the broader incumbent that sponsors evaluate when scouting oral-formulation partners alongside Intract.
  • Evonik (Health Care): CDMO with EUDRACAP®, EUDRAGIT® and other oral-functional excipient/platform technologies used by pharma for enteric and colonic delivery — overlaps with Intract's Phloral® dual-trigger coating positioning.

Emerging players

  • Lyndra Therapeutics: Developer of oral once-weekly sustained-release dosage forms for oral peptides and small molecules — adjacent oral-drug-delivery platform addressing the same patient-compliance thesis (replace frequent dosing/injections with oral formulations).

Others

  • Bioreliance (Merck BioReliance® End-to-End Solutions): Merck's biopharmaceutical testing/services arm — relevant context because Intract has published pre-clinical work with Merck on colon-targeted tofacitinib; Intract sits as a niche complement/competitor rather than a substitute for Merck's broader services.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Intract Pharma social profiles

Digital presence

Intract Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Intract Pharma leadership team

Management profile

Number of profiles

Profiles7 records

Intract Pharma funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Intract Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Intract Pharma

What does Intract Pharma do?

Intract Pharma develops and licenses proprietary oral drug delivery technology platforms that allow biopharmaceutical drugs — including monoclonal antibodies, peptides and proteins — to be administered as tablets or capsules and released at targeted gastrointestinal sites (notably the colon). Its commercial core offerings are the Phloral® dual-trigger enteric coating and the Soteria® oral biologics platform, supported by proprietary GI testing services (Dynamic Dissolution Model and Gastrointestinal Stability/Permeability Models) and enabling release technologies (Duocoat®, ProRelease®, Auto pH System™). Revenue is generated by licensing these technologies to pharma/biotech partners and through collaborative R&D agreements, earning upfront payments, development and regulatory milestones, and royalties.

Is Intract Pharma a public or private company?

Intract Pharma is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Intract Pharma founded?

Intract Pharma was founded in 2015. It employs 11 to 50 people.

Where is Intract Pharma based?

Intract Pharma is headquartered in London, United Kingdom, in the Europe region.

How does Intract Pharma make money?

Two revenue lines are on record. Technology Licensing is the primary driver. The others are collaborative Research & Development.

Who are Intract Pharma's main competitors?

Direct peers on record are Entera Bio, Rani Therapeutics and Applied Molecular Transport. Broad incumbents are Catalent, Lonza (Capsugel) and Evonik (Health Care). Lyndra Therapeutics is listed as an emerging player. Bioreliance (Merck BioReliance® End-to-End Solutions) is listed as an others.

Does Intract Pharma have an API?

No public API is recorded for Intract Pharma.

What industry is Intract Pharma in?

Intract Pharma's product category is Oral Drug Delivery Technologies. Its primary akta.pro industry code is HLAGAHAI, Solid-State Chemistry & Preformulation (Polymorph/Crystallization), with a secondary code of HLAGAHAM, Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Stock TitanTharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of InfliximabTharimmune, Inc. announced a global licensing agreement with Intract Pharma to develop an oral formulation of infliximab, targeting autoimmune diseases. The partnership includes development and commercialization rights to Intract's delivery platform and could improve patient compliance by offering an oral delivery method. This collaboration is expected to enhance Tharimmune's therapeutic pipeline and position it in a multibillion-dollar market for chronic inflammatory disease treatments.PharmiWeb.comTharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of InfliximabTharimmune, Inc. has entered into a definitive agreement to exclusively license INT-023/TH023, an oral formulation of the anti-inflammatory drug infliximab, from Intract Pharma. Under this partnership, Tharimmune acquired global development and commercialization rights outside South Korea, utilizing Intract's Soteria® and Phloral® delivery platform to enable oral administration of the antibody. The deal includes an upfront payment for Intract Pharma and potential future milestone payments and royalties based on net product sales.YahooTharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of InfliximabTharimmune has entered into a definitive agreement to exclusively license Intract Pharma's Soteria and Phloral delivery platform for the development of an oral formulation of infliximab. Under the terms, Tharimmune licensed global rights outside South Korea and secured an existing supply agreement for infliximab, while Intract Pharma received an upfront payment and potential milestone royalties. The partnership aims to overcome challenges in oral antibody delivery to improve patient compliance for autoimmune diseases.IntractpharmaTharimmune Acquires Global Exclusive License to Develop INT-023, an Oral Anti-TNFα mAb for Treatment of Autoimmune DiseasesTharimmune acquired global exclusive development and commercialization rights for INT-023, an oral anti-TNFα monoclonal antibody candidate for autoimmune diseases, from Intract Pharma. Under the agreement, Tharimmune paid a single-digit million dollar upfront fee and is eligible for over $200 million in milestones, while retaining rights to Intract's delivery platform for additional targets. This partnership aims to deliver infliximab orally to improve patient compliance and reduce the burden of intravenous therapies.CPIHelping Innovative Companies Get Novel Biological Therapeutics…A CPI blog post explains biologics — large, complex molecules derived from living organisms, including monoclonal antibodies, vaccines, insulin and growth hormone — and their growing market share, which rose in 2022 with FDA approvals. It outlines CPI's support services, including technology benchmarking, continuous manufacturing, high-throughput development and synthetic DNA manufacturing, citing partners such as 4BaseBio, Touchlight Genetics, Roche and Intract Pharma.PharmiWeb.comBio-Sourcing, Ciloa and Intract Pharma launch €3.4M EU project in inflammatory indications with €1.9M subsidies from EUREKA EurostarsBio-Sourcing, Ciloa, and Intract Pharma launched a €3.4M EU project to develop an oral adalimumab formulation for inflammatory bowel diseases, with €1.9M in EUREKA Eurostars subsidies. The three-year program aims to preclinically validate the product and reach IND-enabling studies.Business Wire BlogBio-Thera Solutions and Intract Pharma Enter Global Collaboration and License Agreement for Soteria® and Phloral® Drug Delivery Technologies to Enable Development of Oral Antibody MedicinesBio-Thera Solutions and Intract Pharma announced a global collaboration and licensing agreement granting Bio-Thera a worldwide license to Intract's Soteria and Phloral oral biologics delivery platform. Intract will receive an undisclosed upfront payment and potential milestones, while Bio-Thera leads manufacturing and commercialization. The partnership aims to develop oral monoclonal antibody treatments for chronic GI inflammatory diseases.